Thryv Therapeutics, Inc.
6 clinical trials · Sponsor
◉ Watch Thryv Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) (NCT07277582) | Thryv Therapeutics, Inc. | 2026-03-07 |
| Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3 (NCT07075445) | Thryv Therapeutics, Inc. | 2025-10-27 |
| Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants (NCT07186946) | Thryv Therapeutics, Inc. | 2025-09-15 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 (NCT06507839) | Thryv Therapeutics, Inc. | 2024-05-15 |
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). (NCT05906732) | Thryv Therapeutics, Inc. | 2023-03-12 |
| Phase 1 Study of LQT-1213 in Healthy Adults (NCT05759962) | Thryv Therapeutics, Inc. | 2022-09-14 |
Track Thryv Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.